{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:16:30Z","timestamp":1775304990526,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["UMO2012\/05\/B\/NZ7\/02459"],"award-info":[{"award-number":["UMO2012\/05\/B\/NZ7\/02459"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["UMO2015\/19\/B\/NZ7\/03694"],"award-info":[{"award-number":["UMO2015\/19\/B\/NZ7\/03694"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Science and Higher Education"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.neulet.2018.12.016","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T03:42:37Z","timestamp":1544586157000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Levetiracetam combined with ACEA, highly selective cannabinoid CB1 receptor agonist changes neurogenesis in mouse brain"],"prefix":"10.1016","volume":"696","author":[{"given":"Miros\u0142aw","family":"Zagaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Haratym-Maj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslaw","family":"Rola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Maj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarogniew J.","family":"\u0141uszczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Andres-Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2018.12.016_bib0005","series-title":"European Medicines Agency: Keppra: EPAR \u2013 Product Information","year":"2014"},{"key":"10.1016\/j.neulet.2018.12.016_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.seizure.2009.06.009","article-title":"Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model","volume":"18","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.neulet.2018.12.016_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2008.12.046","article-title":"Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis","volume":"605","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2006.00364.x","article-title":"Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis","volume":"47","author":"Luszczki","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.neulet.2018.12.016_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1528-1167.2006.00964.x","article-title":"Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model","volume":"48","author":"Luszczki","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.neulet.2018.12.016_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(92)90855-X","article-title":"Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals","volume":"222","author":"Gower","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0920-1211(95)00077-1","article-title":"Effects of levetiracetam, a novel antiepileptic drug, on conversant activity in two genetic rat models of epilepsy","volume":"22","author":"Gower","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","article-title":"Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats","volume":"232","author":"L\u00f6scher","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3565(24)37251-9","article-title":"Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy","volume":"284","author":"L\u00f6scher","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2018.12.016_bib0055","first-page":"782","article-title":"How significant is the difference between drug doses influencing the threshold for electroconvulsions?","volume":"57","author":"Luszczki","year":"2005","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neulet.2018.12.016_bib0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejphar.2013.10.063","article-title":"Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model \u2013 a type II isobolographic analysis","volume":"723","author":"Florek-\u0141uszczki","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2015.01.003","article-title":"Effects of WIN 55, 212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice","volume":"30","author":"Florek-Luszczki","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neulet.2018.12.016_bib0075","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/35087000","article-title":"SV2 modulates the size of the readily releasable pool of secretory vesicles","volume":"3","author":"Xu","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fneur.2013.00172","article-title":"Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke","volume":"4","author":"Shetty","year":"2013","journal-title":"Front Neurol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0085","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.eplepsyres.2006.09.005","article-title":"Administration of levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model","volume":"73","author":"Gibbs","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.yebeh.2011.12.005","article-title":"Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention","volume":"23","author":"Steinbaugh","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neulet.2018.12.016_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12028-009-9304-y","article-title":"Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis","volume":"12","author":"Szaflarski","year":"2010","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.neulet.2018.12.016_bib0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1385\/NCC:5:1:71","article-title":"Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage","volume":"5","author":"H","year":"2006","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.neulet.2018.12.016_bib0105","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/1545968313491007","article-title":"Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury","volume":"27","author":"Zou","year":"2013","journal-title":"Neurorehabil. Neural Repair"},{"key":"10.1016\/j.neulet.2018.12.016_bib0110","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S1734-1140(11)70696-X","article-title":"Neurogenesis in the epileptic brain: a brief overview from temporal lobe epilepsy","volume":"63","author":"Andres-Mach","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neulet.2018.12.016_bib0115","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/3305","article-title":"Neurogenesis in the adult human hippocampus","volume":"4","author":"Eriksson","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.neulet.2018.12.016_bib0120","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1021\/acs.jmedchem.7b01114","article-title":"Multifunctional hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)-3-methoxypropanamides with anticonvulsant and antinociceptive properties","volume":"60","author":"Abram","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0125","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","article-title":"Design, synthesis and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl) propanamidesand2-(2,5-dioxopyrroli-din-1-yl) butanamides","volume":"58","author":"Kami\u0144ski","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bmc.2015.12.027","article-title":"New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones","volume":"24","author":"Kami\u0144ski","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejmech.2012.11.026","article-title":"Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles","volume":"60","author":"Plech","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.pnpbp.2012.07.001","article-title":"Effect of ACEA-a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model","volume":"39","author":"Andres-Mach","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.12.016_bib0145","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/jpet.105.100354","article-title":"Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus","volume":"317","author":"Blair","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2018.12.016_bib0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eplepsyres.2013.06.004","article-title":"CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations","volume":"106","author":"Citraro","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2006.11.030","article-title":"Endocannabinoids block status epilepticus in cultured hippocampal neurons","volume":"558","author":"Deshpande","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0160","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid \u0394-THCV in animal models of Parkinson\u2019s disease","volume":"163","author":"Garcia","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pnpbp.2009.09.005","article-title":"Effect of arachidonyl-2\u2019-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock induced seizure model","volume":"34","author":"Luszczki","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.12.016_bib0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nlm.2013.12.010","article-title":"The endocannabinoid system: an emotional buffer in the modulation of memory function","volume":"112","author":"Morena","year":"2013","journal-title":"Neurobiol. Learn Mem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0175","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1111\/bph.13186","article-title":"The role of cannabinoids in adult neurogenesis","volume":"172","author":"Prenderville","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054271","article-title":"Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells","volume":"8","author":"Compagnucci","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2018.12.016_bib0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.brainres.2010.06.061","article-title":"Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus","volume":"1352","author":"Sugaya","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"M.J. Brodie. Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neulet.2018.12.016_bib0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs-rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.neulet.2018.12.016_bib0200","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","article-title":"Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed","volume":"41","author":"Deckers","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neulet.2018.12.016_bib0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1734-1140(09)70024-6","article-title":"Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions","volume":"61","author":"Luszczki","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neulet.2018.12.016_bib0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2006.07.037","article-title":"Arachidonyl-2\u2019-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model","volume":"547","author":"Luszczki","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0215","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/fcp.12123","volume":"29","author":"Florek-Luszczki","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183873","article-title":"Effects of arachidonyl-2\u2019-chloroethylamide (ACEA) on the protective action of various antiepileptic drugs in the 6-Hz corneal stimulation model in mice","volume":"12","author":"Luszczki","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2018.12.016_bib0225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2015.07.028","article-title":"ACEA (a highly selective cannabinoid CB1 receptor agonist) stimulates hippocampal neurogenesis in mice treated with antiepileptic drugs","volume":"1624","author":"Andres-Mach","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0230","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1073\/pnas.94.6.2238","article-title":"Molecular characterization of human and mouse fatty acid amide hydrolases","volume":"94","author":"Giang","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2018.12.016_bib0235","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0022-3565(24)37121-6","article-title":"The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity","volume":"283","author":"Compton","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2018.12.016_bib0240","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/ijms18050900","article-title":"A long-term treatment with arachidonyl-2\u2019-chloroethylamide combined with valproate increases neurogenesis in a mouse pilocarpine model of epilepsy","volume":"18","author":"Andres-Mach","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0245","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0360-3016(01)02720-1","article-title":"Ki-67: a prognostic factor for low-grade glioma?","volume":"52","author":"Fisher","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neulet.2018.12.016_bib0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-0270(02)00007-9","article-title":"The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis","volume":"115","author":"Kee","year":"2002","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neulet.2018.12.016_bib0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285608094212","article-title":"Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited","volume":"1","author":"Surges","year":"2008","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.neulet.2018.12.016_bib0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ern.10.3","article-title":"Levetiracetam: a comprehensive review","volume":"10","author":"Crepeau","year":"2010","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.neulet.2018.12.016_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2009.02.040","article-title":"Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy","volume":"1266","author":"Ueda","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2018.12.016_bib0270","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10571-006-9132-y","article-title":"Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures","volume":"27","author":"Oliveira","year":"2007","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0275","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbd.2006.12.014","article-title":"Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus","volume":"26","author":"Howell","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neulet.2018.12.016_bib0280","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.expneurol.2004.11.016","article-title":"Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats","volume":"192","author":"Scharfman","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0285","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1073\/pnas.101034998","article-title":"FGF-2 regulation of neurogenesis in adult hippocampus after brain injury","volume":"98","author":"Yoshimura","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2018.12.016_bib0290","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.yebeh.2003.12.004","volume":"5","author":"Husum","year":"2004","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neulet.2018.12.016_bib0295","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1471-4159.2003.01979.x","article-title":"Hippocampal neurotrophin levels in a kainate model of temporal lobe epilepsy: a lack of correlation between brain-derived neurotrophic factor content and progression of aberrant dentate mossy fiber sprouting","volume":"87","author":"Shetty","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0300","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0022-3565(24)38289-8","article-title":"Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)","volume":"289","author":"Hillard","year":"1999","journal-title":"J. Pharmacol. Exp.Ther."},{"key":"10.1016\/j.neulet.2018.12.016_bib0305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1471-4159.1991.tb06379.x","article-title":"Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum","volume":"57","author":"Bidaut-Russell","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0310","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1016\/0006-2952(89)90628-X","article-title":"Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies","volume":"38","author":"Howlett","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0315","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1523\/JNEUROSCI.18-01-00451.1998","article-title":"Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia","volume":"18","author":"Richardson","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0320","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1523\/JNEUROSCI.16-14-04322.1996","article-title":"Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures","volume":"16","author":"Shen","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0325","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/mol.66.2.204","article-title":"Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice","volume":"66","author":"Jin","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0330","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1460-9568.2007.05322.x","article-title":"CB2 cannabinoid receptors promote mouse neural stem cell proliferation","volume":"25","author":"Molina-Holgado","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0335","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.mcn.2008.03.010","article-title":"The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation","volume":"38","author":"Rubio-Araiz","year":"2008","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0340","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1523\/JNEUROSCI.1683-10.2010","article-title":"Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum","volume":"30","author":"De Chiara","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0345","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2009.10.011","article-title":"BDNF regulates neuronal sensitivity to endocannabinoids","volume":"467","author":"Maison","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2018.12.016_bib0350","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1152\/jn.00472.2010","article-title":"BDNF evokes release of endogenous cannabinoids at layer 2\/3 inhibitory synapses in the neocortex","volume":"104","author":"Lemtiri-Chlieh","year":"2010","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0355","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1523\/JNEUROSCI.0653-13.2013","article-title":"Fascin regulates the migration of subventricular zone-derived neuroblasts in the postnatal brain","volume":"33","author":"Sonego","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2018.12.016_bib0360","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1083\/jcb.200210164","article-title":"The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response","volume":"160","author":"Williams","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.neulet.2018.12.016_bib0365","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1042\/BST20130198","article-title":"Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1\u03b2 (IL-1\u03b2) signalling","volume":"41","author":"Garcia-Ovejero","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neulet.2018.12.016_bib0370","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jnc.13288","article-title":"Cannabinoid receptor type 1 agonist ACEA improves motor recovery and protects neurons in ischemic stroke in mice","volume":"135","author":"Caltana","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2018.12.016_bib0375","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuropharm.2018.03.024","article-title":"Inhibition of mitochondrial permeability transition pore opening contributes to cannabinoid type 1 receptor agonist ACEA-induced neuroprotection","volume":"135","author":"Ma","year":"2018","journal-title":"Neuropharmacology"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018308619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018308619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:39:00Z","timestamp":1775302740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394018308619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":75,"alternative-id":["S0304394018308619"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2018.12.016","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam combined with ACEA, highly selective cannabinoid CB1 receptor agonist changes neurogenesis in mouse brain","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2018.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}